Payment overview · 2025
General Payments
$438.74
15 reported records · 9 companies
Healthcare provider profile · identity verified
Rafael Abreu, M.D
Allopathic & Osteopathic Physicians|Family Medicine · HIALEAH, FL · NPI 1265769822
Verified facts
What the public records show
CMS Open Payments records show Rafael Abreu, M.D received $438.74 in general payments during 2025 across 15 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 36.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 674 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 674 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $158.31 | 36.1% | 6 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $128.20 | 29.2% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $28.09 | 6.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $24.62 | 5.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.68 | 5.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.99 | 5.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.98 | 4.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.97 | 4.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.90 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $438.74 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $158.31 | 6 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $128.20 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $40.96 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $28.09 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 674 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
674 | 141 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
674 | 141 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 936 | 159 |
| Eliquis | Apixaban | 674 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 636 | 112 |
| Montelukast Sodium | Montelukast Sodium | 588 | 74 |
| Famotidine | Famotidine | 582 | 91 |
| Losartan Potassium | Losartan Potassium | 548 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 534 | 78 |
| Furosemide | Furosemide | 524 | 121 |
| Lisinopril | Lisinopril | 508 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 508 | 74 |
| Metformin Hcl | Metformin Hcl | 501 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 500 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 499 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 463 | 99 |
| Gabapentin | Gabapentin | 403 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 390 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 377 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 358 | 72 |
| Lactulose | Lactulose | 344 | 54 |
| Omeprazole | Omeprazole | 288 | 58 |
| Ammonium Lactate | Ammonium Lactate | 271 | 43 |
| Trazodone Hcl | Trazodone Hcl | 263 | 45 |
| Carvedilol | Carvedilol | 257 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 249 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 229 | 42 |
| Levetiracetam | Levetiracetam | 227 | 28 |
| Mirtazapine | Mirtazapine | 225 | 45 |
| Memantine Hcl | Memantine Hcl | 224 | 39 |
| Ketoconazole | Ketoconazole | 218 | 38 |
| Azithromycin | Azithromycin | 210 | 161 |
| Simvastatin | Simvastatin | 208 | 30 |
| Finasteride | Finasteride | 201 | 29 |
| Latanoprost | Latanoprost | 201 | 27 |
| Donepezil Hcl | Donepezil Hcl | 188 | 31 |
| Glipizide | Glipizide | 168 | 22 |
| Ssd | Silver Sulfadiazine | 158 | 29 |
| Mupirocin | Mupirocin | 155 | 52 |
| Cefdinir | Cefdinir | 153 | 143 |
| Potassium Chloride | Potassium Chloride | 153 | 28 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 149 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 148 | 27 |
| Januvia | Sitagliptin Phosphate | 148 | 22 |
| Mounjaro | Tirzepatide | 146 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 145 | 37 |
| Sertraline Hcl | Sertraline Hcl | 140 | 27 |
| Buspirone Hcl | Buspirone Hcl | 139 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 134 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 20 |
| Xarelto | Rivaroxaban | 127 | 16 |
| Entresto | Sacubitril/Valsartan | 117 | 24 |
| Nifedipine Er | Nifedipine | 112 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 103 | 19 |
| Megestrol Acetate | Megestrol Acetate | 96 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 94 | 25 |
| Ibuprofen | Ibuprofen | 94 | 25 |
| Brimonidine Tartrate | Brimonidine Tartrate | 92 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 91 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 85 | suppressed |
| Levofloxacin | Levofloxacin | 82 | 71 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 81 | 11 |
| Spironolactone | Spironolactone | 81 | 23 |
| Alendronate Sodium | Alendronate Sodium | 80 | 15 |
| Enalapril Maleate | Enalapril Maleate | 77 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 57 |
| Humalog Kwikpen U-100 | Insulin Lispro | 76 | 12 |
| Divalproex Sodium | Divalproex Sodium | 75 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 75 | 66 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 73 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 71 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 16 |
| Trulicity | Dulaglutide | 71 | suppressed |
| Sucralfate | Sucralfate | 69 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 68 | 12 |
| Midodrine Hcl | Midodrine Hcl | 66 | 17 |
| Novolin R | Insulin Regular, Human | 66 | 12 |
| Allopurinol | Allopurinol | 65 | 16 |
| Methylprednisolone | Methylprednisolone | 65 | 59 |
| Bumetanide | Bumetanide | 63 | 18 |
| Nystatin | Nystatin | 62 | 25 |
| Prednisone | Prednisone | 62 | 24 |
| Gemtesa | Vibegron | 61 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 59 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 12 |
| Olanzapine | Olanzapine | 57 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 54 | 18 |
| Arnuity Ellipta | Fluticasone Furoate | 52 | suppressed |
| Cilostazol | Cilostazol | 52 | suppressed |
| Metronidazole | Metronidazole | 51 | 48 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 51 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 48 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 46 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 44 | suppressed |
| Torsemide | Torsemide | 43 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | 13 |
| Labetalol Hcl | Labetalol Hcl | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Baclofen | Baclofen | 39 | 12 |
| Enulose | Lactulose | 39 | 12 |
| Hydrocortisone | Hydrocortisone | 39 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 38 | suppressed |
| Folic Acid | Folic Acid | 38 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 36 | 14 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 36 | 21 |
| Adlarity | Donepezil Hcl | 35 | suppressed |
| Brilinta | Ticagrelor | 35 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 28 |
| Valsartan | Valsartan | 34 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Budesonide | Budesonide | 33 | 13 |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 33 | suppressed |
| Dexamethasone | Dexamethasone | 32 | 31 |
| Humulin R | Insulin Regular, Human | 32 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 31 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 31 | suppressed |
| Timolol Maleate | Timolol Maleate | 31 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 30 | suppressed |
| Clotrimazole | Clotrimazole | 30 | suppressed |
| Levemir | Insulin Detemir | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 30 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Carbamazepine Er | Carbamazepine | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 16 |
| Ciclopirox | Ciclopirox | 25 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Temazepam | Temazepam | 25 | 12 |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Pentoxifylline | Pentoxifylline | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | 11 |
| Celecoxib | Celecoxib | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | 23 |
| Santyl | Collagenase Clostridium Hist. | 23 | 11 |
| Anastrozole | Anastrozole | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 11 |
| Prednisolone Acetate | Prednisolone Acetate | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Ertapenem | Ertapenem Sodium | 21 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Ingrezza | Valbenazine Tosylate | 19 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | 15 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Rhopressa | Netarsudil Mesylate | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Paricalcitol | Paricalcitol | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $438.74 · 15 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AREXVY, CAPLYTA, ELIQUIS, FARXIGA, LifeVest, NURTEC ODT, REXULTI, REZDIFFRA, SHINGRIX, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error